{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:07:17Z","timestamp":1782918437245,"version":"3.54.5"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008982","name":"Qatar National Research Fund","doi-asserted-by":"publisher","award":["UREP 16-012-3-003"],"award-info":[{"award-number":["UREP 16-012-3-003"]}],"id":[{"id":"10.13039\/100008982","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>Even though all guidelines recommend generally against antipsychotic polypharmacy, antipsychotic polypharmacy appears to be a very common practice across the globe. This study aimed to examine the prescription patterns of antipsychotics in Qatar, in comparison with the international guidelines, and to scrutinize the sociodemographic and clinical features associated with antipsychotic polypharmacy.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>All the medical records of all the inpatients and outpatients treated by antipsychotics at the Department of Psychiatry\u2013Hamad Medical Corporation (HMC) in Doha, Qatar (between October 2012 and April 2014) were retrospectively analyzed. We retrieved the available sociodemographic data, psychiatric features, and details on the medication history.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Our sample consisted of 537 individuals on antipsychotics (2\/3 were male; mean age 33.8\u00b110.2 years), prescribed for a psychotic disorder in 57%, a mood disorder in 9.3%, and various other diagnoses in 33.7%. About 55.9% received one antipsychotic, 29.6% received two antipsychotics, and 14.5% received more than two antipsychotics. Polypharmacy was associated with younger age (p = 0.025), being single (p&lt;0.001), the diagnosis of a psychotic disorder (p&lt;0.001), and previous admissions to psychiatry (p&lt;0.001).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Antipsychotic polypharmacy appears to be quite common in Qatar, as it is the case in many other countries, in contrast with most international recommendations. Studies are needed to explore the reasons behind this disparity.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0241986","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T18:36:58Z","timestamp":1604947018000},"page":"e0241986","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Patterns of prescription of antipsychotics in Qatar"],"prefix":"10.1371","volume":"15","author":[{"given":"Sami","family":"Ouanes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imen","family":"Becetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhaila","family":"Ghuloum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Hammoudeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mena","family":"Shehata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Ghabrash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6669-8470","authenticated-orcid":true,"given":"Areej","family":"Yehya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hawra","family":"Al-Lawati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8206-3774","authenticated-orcid":true,"given":"Nora","family":"Al-Fakhri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huma","family":"Iram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nighat","family":"Ajmal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yassin","family":"Eltorki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6358-1541","authenticated-orcid":true,"given":"Hassen","family":"Al-Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,11,9]]},"reference":[{"key":"pone.0241986.ref001","first-page":"1","article-title":"A systematic review of clinical guidelines on choice, dose, and duration of antipsychotics treatment in first- and multi-episode schizophrenia","volume":"2019","author":"CLM Hui","journal-title":"International review of psychiatry"},{"issue":"9","key":"pone.0241986.ref002","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/0706743717720448","article-title":"Guidelines for the Pharmacotherapy of Schizophrenia in Adults.","volume":"62","author":"G Remington","year":"2017","journal-title":"Canadian journal of psychiatry Revue canadienne de psychiatrie"},{"issue":"2","key":"pone.0241986.ref003","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4088\/JCP.v63n0201","article-title":"Antipsychotic polypharmacy: squandering precious resources","volume":"63","author":"SM Stahl","year":"2002","journal-title":"The Journal of clinical psychiatry"},{"issue":"4","key":"pone.0241986.ref004","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/0269881114562090","article-title":"\"First do no harm.\" A systematic review of the prevalence and management of antipsychotic adverse effects","volume":"29","author":"SL Young","year":"2015","journal-title":"Journal of psychopharmacology"},{"key":"pone.0241986.ref005","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1192\/bjp.188.2.122","article-title":"Schizophrenia, neuroleptic medication and mortality","volume":"188","author":"M Joukamaa","year":"2006","journal-title":"The British journal of psychiatry: the journal of mental science"},{"issue":"1","key":"pone.0241986.ref006","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/wps.20387","article-title":"Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis","volume":"16","author":"B Galling","year":"2017","journal-title":"World psychiatry: official journal of the World Psychiatric Association"},{"issue":"5","key":"pone.0241986.ref007","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamapsychiatry.2018.4320","article-title":"Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia","volume":"76","author":"J Tiihonen","year":"2019","journal-title":"JAMA psychiatry"},{"issue":"2","key":"pone.0241986.ref008","doi-asserted-by":"crossref","first-page":"128","DOI":"10.9758\/cpn.2014.12.2.128","article-title":"Prescription patterns for patients with schizophrenia in Korea: a focus on antipsychotic polypharmacy.","volume":"12","author":"HY Kim","year":"2014","journal-title":"Clinical psychopharmacology and neuroscience: the official scientific journal of the Korean College of Neuropsychopharmacology"},{"issue":"5","key":"pone.0241986.ref009","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/YIC.0000000000000024","article-title":"Socioeconomic factors influencing antipsychotic prescription for schizophrenia inpatients in China: a cross-sectional study.","volume":"29","author":"Q Xue","year":"2014","journal-title":"International clinical psychopharmacology"},{"issue":"1","key":"pone.0241986.ref010","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.schres.2012.03.018","article-title":"Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009","volume":"138","author":"JA Gallego","year":"2012","journal-title":"Schizophrenia research"},{"key":"pone.0241986.ref011","article-title":"Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis","author":"K Matsui","year":"2019","journal-title":"Schizophrenia research"},{"key":"pone.0241986.ref012","first-page":"915","article-title":"Use of second-generation antipsychotics in the acute inpatient management of schizophrenia in the Middle East","volume":"11","author":"S Alkhadhari","year":"2015","journal-title":"Neuropsychiatric disease and treatment"},{"issue":"4","key":"pone.0241986.ref013","first-page":"00140","article-title":"Prevalence of Antipsychotic Polypharmacy: Prescribing Practices at the Psychiatry Department at HMC (Hamad Medical Corporation, Doha, Qatar).","volume":"3","author":"A Zaraa","year":"2015"},{"issue":"3","key":"pone.0241986.ref014","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2174\/0929867043456070","article-title":"A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation","volume":"11","author":"SM Stahl","year":"2004","journal-title":"Current medicinal chemistry"},{"key":"pone.0241986.ref015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ajp.2018.03.012","article-title":"Prevalence and correlates of antipsychotic polypharmacy in Hong Kong","volume":"33","author":"SLM Lung","year":"2018","journal-title":"Asian journal of psychiatry"},{"issue":"5","key":"pone.0241986.ref016","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1034\/j.1600-0447.2002.01331.x","article-title":"Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations","volume":"106","author":"O Freudenreich","year":"2002","journal-title":"Acta psychiatrica Scandinavica"},{"issue":"3","key":"pone.0241986.ref017","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4997\/JRCPE.2018.306","article-title":"Cognitive bias in clinical medicine","volume":"48","author":"ED O'Sullivan","year":"2018","journal-title":"The journal of the Royal College of Physicians of Edinburgh"},{"issue":"6","key":"pone.0241986.ref018","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4088\/JCP.v64n0607","article-title":"Chlorpromazine equivalent doses for the newer atypical antipsychotics","volume":"64","author":"SW Woods","year":"2003","journal-title":"The Journal of clinical psychiatry"},{"key":"pone.0241986.ref019","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR: American Psychiatric Association; 2000."},{"issue":"3","key":"pone.0241986.ref020","first-page":"368","article-title":"Associated factors with antipsychotic use in assisted living facilities: a cross-sectional study of 4367 residents","volume":"40","author":"A Larrayadieu","year":"2011","journal-title":"Age and"},{"key":"pone.0241986.ref021","article-title":"Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries: Fourth survey of Research on Asian Prescription Patterns on antipsychotics","author":"SY Yang","year":"2018","journal-title":"Psychiatry and clinical neurosciences"},{"issue":"6","key":"pone.0241986.ref022","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/j.1440-1819.2006.01601.x","article-title":"Prescription pattern of antipsychotic drugs for schizophrenic inpatients in Japan: research on East Asia Psychotropic Prescription Pattern-Antipsychotics study","volume":"60","author":"R Yoshimura","year":"2006","journal-title":"Psychiatry and clinical neurosciences"},{"issue":"1480","key":"pone.0241986.ref023","first-page":"61","article-title":"Antipsychotic prescribing in New Zealand between 2008 and 2015","volume":"131","author":"S Wilkinson","year":"2018","journal-title":"The New Zealand medical journal"},{"key":"pone.0241986.ref024","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2174\/1745017901713010092","article-title":"Antipsychotic Use Pattern in Schizophrenia Outpatients: Correlates of Polypharmacy","volume":"13","author":"E Yazici","year":"2017","journal-title":"Clinical practice and epidemiology in mental health: CP & EMH"},{"issue":"2","key":"pone.0241986.ref025","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1176\/appi.ps.201300180","article-title":"Geographic and clinical variation in clozapine use in the United States","volume":"65","author":"TS Stroup","year":"2014","journal-title":"Psychiatric services"},{"issue":"3","key":"pone.0241986.ref026","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/2045125316683151","article-title":"Prescribing pattern of clozapine and other antipsychotics for patients with first-episode psychosis: a cross-sectional survey of early intervention teams.","volume":"7","author":"TE Tungaraza","year":"2017","journal-title":"Therapeutic advances in psychopharmacology"},{"key":"pone.0241986.ref027","first-page":"1","article-title":"Treatment resistant schizophrenia\u2014review and a call to action","volume":"2018","author":"J Lally","journal-title":"Irish journal of psychological medicine"},{"issue":"6","key":"pone.0241986.ref028","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1176\/appi.ps.201600041","article-title":"Prescribing of Clozapine and Antipsychotic Polypharmacy for Schizophrenia in a Large Medicaid Program","volume":"68","author":"Y Tang","year":"2017","journal-title":"Psychiatric services"},{"key":"pone.0241986.ref029","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ajp.2018.12.011","article-title":"A qualitative exploration of clozapine prescribing and monitoring practices in the Arabian Gulf countries","volume":"39","author":"D Ismail","year":"2019","journal-title":"Asian journal of psychiatry"},{"issue":"6","key":"pone.0241986.ref030","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1192\/bjp.bp.111.105833","article-title":"Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation.","volume":"201","author":"OD Howes","year":"2012","journal-title":"The British journal of psychiatry: the journal of mental science"},{"issue":"2","key":"pone.0241986.ref031","doi-asserted-by":"crossref","first-page":"91","DOI":"10.33160\/yam.2018.06.001","article-title":"Negative Symptoms and Cognitive Impairments in Schizophrenia: Two Key Symptoms Negatively Influencing Social Functioning","volume":"61","author":"K Kaneko","year":"2018","journal-title":"Yonago acta medica"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0241986","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T18:37:33Z","timestamp":1604947053000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0241986"}},"subtitle":[],"editor":[{"given":"Vincenzo","family":"De Luca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0241986","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,9]]}}}